Vadastuximab talirine
Vadastuximab talirine (pronunciation: vuh-dah-stuhk-see-mab tah-leer-een) is a monoclonal antibody-drug conjugate designed for the treatment of acute myeloid leukemia (AML) and other CD33-expressing hematologic malignancies.
Etymology
The name "Vadastuximab talirine" is derived from the components of the drug. "Vada" is a prefix used in pharmacology for monoclonal antibodies, "stux" refers to the target of the antibody, CD33, and "imab" indicates that it is a fully human antibody. "Talirine" refers to the cytotoxic agent that is conjugated to the antibody.
Mechanism of Action
Vadastuximab talirine binds to the CD33 antigen, which is expressed on the surface of myeloid leukemia cells. Upon binding, the drug is internalized and the cytotoxic agent is released, causing cell death.
Clinical Trials
Vadastuximab talirine has been evaluated in several clinical trials for the treatment of acute myeloid leukemia (AML) and other CD33-expressing hematologic malignancies. However, the development of the drug was discontinued in 2017 due to safety concerns.
Related Terms
See Also
External links
- Medical encyclopedia article on Vadastuximab talirine
- Wikipedia's article - Vadastuximab talirine
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski